Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast ButtonSwitch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Stay Informed: Medical and Research Updates
Connect With Us!
 

 

A Protein Controlling Blood Pressure Can Enhance Immune Cells to Attack Alzheimer's Plaques

BrightFocus-funded research could lead to a new type of treatment

February 19, 2014
Source: Journal of Clinical Investigation

Summary: What can be bad for you in one situation may be good for you in another. BrightFocus-funded Dr. Maya Koronyo-Hamaoui is the senior author on a groundbreaking publication that reported the ACE protein, which can increase blood pressure to dangerous levels in the body’s blood stream, can actually help to clear beta-amyloid in the brain by stimulating the immune system.

Dr. Maya Koronyo-Hamaoui

The researchers found that genetically overproducing ACE in certain scavenging immune cells (called monocytes) that respond to inflammation helped to target and break down the toxic beta amyloid protein, and prevented cognitive decline in mice genetically engineered to show features of Alzheimer’s disease. Overexpression of ACE in just the immune cells had no effect on the blood pressure of the body. However, this brain beta-amyloid clean-up was prevented by giving the mice an ACE inhibitor drug, called ramipril, a type of blood pressure medication.

Therefore, it seems that the natural protein-busting capabilities of ACE, when present at high levels in the body’s blood stream, can have bad effects on blood pressure; however, when ACE is expressed at high levels in immune cells, it can have good effects on fighting plaque deposits in the brain.

What do these findings mean for patients with Alzheimer’s disease? There is much work that needs to be done before scientists can consider translating a potential strategy for delivering ACE-overexpressing monocytes to patients. However, these studies have demonstrated that a combination approach to treating Alzheimer’s, in this case increasing immune response to inflammation paired with delivery of a beta-amyloid-busting protein, might be the best way forward to reducing disease symptoms and improving cognitive function.

View all news updates for Alzheimer's disease


Disclaimer: The information provided in this section is a public service of the BrightFocus Foundation, and should not in any way substitute for the advice of a qualified healthcare professional, and is not intended to constitute medical advice. Although we take efforts to keep the medical information on our website updated, we cannot guarantee that the information on our website reflects the most up-to-date research. Please consult your physician for personalized medical advice; all medications and supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical product or therapy.

Some of the content in this section is adapted from other sources, which are clearly identified within each individual item of information.

Shop for a Cause YouTube Twitter Connect With Us Pinterest Google+